Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest (1992) 47.46

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol (2004) 5.19

The pharmacodynamics of beta-lactams. Clin Infect Dis (1998) 3.54

Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest (2012) 2.45

In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother (1998) 1.94

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci (2002) 1.72

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother (2004) 1.70

Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med (2013) 1.63

Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet (1994) 1.59

Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents (2015) 1.54

In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob Agents Chemother (2008) 1.51

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother (2005) 1.50

Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother (2005) 1.50

In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2009) 1.43

Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med (1988) 1.41

Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother (2010) 1.33

Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet (2006) 1.29

Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci (1997) 1.24

Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care (2013) 1.20

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care (2012) 1.18

Doripenem. Clin Infect Dis (2009) 1.15

Ethnic variation in fat and lean body mass and the association with insulin resistance. J Clin Endocrinol Metab (2009) 1.14

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother (2005) 1.11

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07

Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents (2012) 1.02

Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother (2010) 1.01

Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med (2013) 0.97

Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother (2012) 0.95

Simultaneous determination of eight β-lactam antibiotics in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.93

Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother (2008) 0.91

Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents (2010) 0.89

Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents (2008) 0.87

How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents (2012) 0.87

Overview of seizure-inducing potential of doripenem. Drug Saf (2009) 0.87

Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs. J Clin Microbiol (2014) 0.84

Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet (2015) 0.83

Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol (2015) 0.83

Population pharmacokinetics of levofloxacin in Korean patients. J Chemother (2016) 0.82

Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. Int J Antimicrob Agents (2010) 0.81

Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia. Ann Pharmacother (2012) 0.80

Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. J Antimicrob Chemother (2014) 0.80

A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.80

Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J Infect Chemother (2010) 0.79

Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. Int J Antimicrob Agents (2012) 0.79

Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock. J Clin Pharmacol (2014) 0.78

Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. Ann Pharmacother (2013) 0.78

Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment. J Infect Chemother (2014) 0.77

Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. Antimicrob Agents Chemother (2015) 0.76

Application of Pharmacodynamic Profiling for the Selection of Optimal β-lactam Regimens in a Large University Hospital. Int J Infect Dis (2016) 0.76

Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother (2016) 0.76

Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents (2006) 0.76

In vitro Antibacterial Activity of Doripenem against Gram-Negative Blood Isolates in a Korean Tertiary Care Center. Infect Chemother (2015) 0.76